Neurocrine Biosciences confirmed that NBI‑1070770, an oral NR2B negative allosteric modulator licensed from Takeda, failed to meet the primary endpoint in a Phase 2 trial for major depressive disorder. The company reported the midstage negative in a corporate update and follow‑up filings; executives said safety signals were acceptable but efficacy did not separate from placebo. Analysts noted this marks a second clinical disappointment for Neurocrine from Takeda‑sourced assets and said the company will re‑evaluate portfolio priorities. Neurocrine will continue analyzing trial data to decide next steps for the program while maintaining investment in its other psychiatry and neurologic candidates.